Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $4M (up 25106.7% year over year) with net income of −$73M.
Q2 2026 key financials · XBRL
- Revenue
- $4M
- +25106.7% YoY · +24.1% QoQ
- Net income
- −$73M
- −33.4% YoY · −6.1% QoQ
- Operating margin
- -2037.2%
- EPS (diluted)
- −$1.04
- −6.1% YoY · −3.0% QoQ
Source: XBRL data from the 4D Molecular Therapeutics, Inc. (FDMT) Q2 2026 10-Q on SEC EDGAR. USD.
4D Molecular Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $3.8M, up $3.8M YoY, driven by Otsuka clinical-trial cost sharing and reimbursements
- Operating loss $77.0M vs $59.5M YoY; net loss $72.9M vs $54.7M
- 4D-150 R&D $43.6M, up 128% YoY, making it the largest development spend
- Cash, equivalents and marketable securities $430.6M; $20.0M Hercules borrowing outstanding
- Topline data expected 4FRONT-1 in Q2 2027 and 4FRONT-2 in the second half of 2027; additional funding required
Risk Factors
- Newly added debt risk: June 2026 Hercules agreement provides up to $200.0 million, with $20.0 million funded at closing
- Most materially updated financial risk: $430.6 million cash and securities expected to fund planned operations for at least one year
- Regulatory risk: evolving FDA, EMA and NIH requirements may require additional studies, increasing costs and delaying approvals
- Operational risk: manufacturing scale-up and supply-chain execution could delay clinical development or commercialization
- Financial risk: Hercules debt bears floating-rate interest and matures June 1, 2031, increasing exposure to prime-rate changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 4D Molecular Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.